Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LSS | P48449 | 3/20 | 0.49 |
| ▸ | CACNA1H | O95180 | 2/20 | 0.47 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.47 |
| ▸ | PSEN1 | P49768 | 2/20 | 0.46 |
| ▸ | PSEN2 | P49810 | 2/20 | 0.46 |
| ▸ | APH1B | Q8WW43 | 2/20 | 0.46 |
| ▸ | NCSTN | Q92542 | 2/20 | 0.46 |
| ▸ | APH1A | Q96BI3 | 2/20 | 0.46 |
| ▸ | PSENEN | Q9NZ42 | 2/20 | 0.46 |
| ▸ | ATP4A | P20648 | 2/20 | 0.46 |
| ▸ | ATP4B | P51164 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3365715 | 0.95 | LSS (0.54) | LSSCACNA1HCACNA1BPSEN1PSEN2 | |
| SCHEMBL3365014 | 0.94 | LSS (0.53) | LSSCACNA1HCACNA1BL3MBTL1SERPINE1 | |
| SCHEMBL3366865 | 0.92 | LSS (0.58) | LSSCACNA1HCACNA1BPSEN1PSEN2 | |
| SCHEMBL3367913 | 0.92 | CACNA1H (0.48) | LSSCACNA1HCACNA1BPSEN1PSEN2 | |
| SCHEMBL3365125 | 0.91 | LSS (0.56) | LSSCACNA1HCACNA1BPSEN1PSEN2 | |
| SCHEMBL3368655 | 0.89 | FFAR1 (0.51) | CACNA1HCACNA1BL3MBTL1 | |
| SCHEMBL3368206 | 0.89 | CACNA1H (0.49) | LSSCACNA1HCACNA1BPSEN1PSEN2 | |
| SCHEMBL3364908 | 0.88 | CACNA1H (0.48) | LSSCACNA1HCACNA1BPSEN1PSEN2 | |
| SCHEMBL3366991 | 0.87 | CACNA1B (0.60) | CACNA1HCACNA1BPSEN1PSEN2APH1B | |
| SCHEMBL3364928 | 0.86 | L3MBTL1 (0.47) | L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1303503-B1 | ANILINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2010-01-27 | — | — | EP | disclosed |
| CN-1208329-C | Novel aniline derivative | HOFFMANN LA ROCHE (CH) | 2005-06-29 | — | — | CN | disclosed |
| US-6683201-B2 | FOR THERAPY AND PROPHYLAXIS OF HYPERCHOLESTEROLEMIA, HYPERLIPEMIA, ARTERIOSCLEROSIS, VASCULAR DISEASES, MYCOSES, PARASITE INFECTIONS, GALLSTONES, TUMORS AND/OR HYPERPROLIFERATIVE DISORDERS, DIABETES | HOFFMANN-LA ROCHE INC. | 2004-01-27 | — | — | US | disclosed |
| CN-1443179-A | Aniline derivatives | HOFFMANN LA ROCHE (CH) | 2003-09-17 | — | — | CN | disclosed |
| EP-1303503-A2 | ANILINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2003-04-23 | — | — | EP | disclosed |
| US-20020038025-A1 | Analine derivatives as OSC inhibitors | F.HOFFMANN-LA ROCHE AG (CH) | 2002-03-28 | — | — | US | disclosed |
| WO-2002006189-A2 | ANILINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2002-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020038025-A1 | Analine derivatives as OSC inhibitors | LSS, CYP51A1, CYP46A1 | LSS 1/4885CACNA1H 1926/4885CACNA1B 2736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.